1、novotech-JANUARY 24,2024Duchenne Muscular Dystrophy-Global Clinical Trial Landscape(2024)North Americaand Europe conducted 60%of DMD trials,with the UK leading in Europe and the US dominating in North AmericaAPAC contrib-uted around 30%of DMD trials,led by Australia and JapanEurope shows shorter rec

2、ruitment durations and faster recruitment rates compared to Asia-Pacific and the US60%30%DMD,a genetic disorder,results in progressive muscle weakness and skeletal degenera-tion.DMD afects 1 in 5,000 males globally,with 20,000 new yearly diagnoses.Both Small Molecules and Antisense Oligonucleotides

3、constitute promi-nent categories among the marketed drugs for DMDMarketed drugs for DMD treatments include Casimersen,Viltolarsen,Deflazacort,and Delandistrogene Moxeparvovec,available globallyDidyouknow?In Europe,Sweden and Norway reported a relatively higher prevalence of DMDThe United States and

4、Canada reported higher prevalence rates of DMDIn Asia,China reported a relatively high prevalence,indicating a substantial burden1 in 5,000The content of this publication is proprietary to Novotech Health Holdings.No part of this publication may be reproduced,distributed,or transmitted in any form o

5、r by any means,including photocopying,recording,or other electronic or mechanical methods,without the prior written permission of Novotech except in the case of quotations embodied in reviews and non-commercial uses.Please note that this copyright statement applies specifically to this publication a

6、nd its content and does not extend to other materials or intellectual property owned by Novotech.Any unauthorized reproduction or distribution of this publication or any portion thereof may result in legal action taken by Novotech to protect its rights.For permissions or inquiries,please contact:com